This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 1 of 1 for:    NCT00148447
Previous Study | Return to List | Next Study

The Efficacy of Escitalopram for Negative Symptoms in Schizophrenia

This study has been completed.
Lundbeck Israel
Information provided by:
BeerYaakov Mental Health Center Identifier:
First received: September 6, 2005
Last updated: May 2, 2007
Last verified: February 2007
The aim of this study is to evaluate the therapeutic effect of escitalopram in the treatment of negative symptoms in schizophrenia patients in a double-blind placebo-controlled study.

Condition Intervention Phase
Schizophrenia Drug: escitalopram Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Placebo-Controlled Trial of Cipralex in the Treatment of Negative Symptoms in Schizophrenia

Resource links provided by NLM:

Further study details as provided by BeerYaakov Mental Health Center:

Primary Outcome Measures:
  • negative symptoms
  • social function

Secondary Outcome Measures:
  • positive symptoms
  • Clinical Global Impression (CGI)
  • depression

Estimated Enrollment: 40
Study Start Date: November 2004
Estimated Study Completion Date: September 2005
Detailed Description:
The aim of this study is to evaluate the therapeutic effect of escitalopram (cipralex) in the treatment of negative symptoms in schizophrenic patients receiving either typical or the newer atypical antipsychotics (olanzapine and risperidone) in a double-blind placebo-controlled study. As there is no drug treatment that is considered as first-line treatment in the treatment of negative symptoms, we thought that the comparison with placebo is plausible. However, it is important to note that the patients will receive the commonly used treatment for their disorder (i.e. antipsychotic medication).

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Chronic schizophrenia patients,
  • Age <60,
  • Medicated,
  • Inpatients and outpatients,on stable doses of antipsychotic medications for at least one month before the study entry.
  • Patients will be clinically stable and free of any additional axis I diagnosis or significant medical illnesses before enrollment into the study.
  • A Positive and Negative Syndrome Scale (PANSS) score of 50 or above will be required for entry to the study.

Exclusion Criteria:

  • Comorbidity with mania or major depression,
  • Pregnancy,
  • Lactation,
  • Impaired renal or hepatic function,
  • History of sensitivity to cipramil or to other drugs from the selective serotonin reuptake inhibitor (SSRI) group.
  • Additional exclusion criteria will consist of mental retardation, organic conditions (brain tumors, drug abuse) and severe exacerbation of the psychiatric condition (i.e. suicide attempt, severe psychotic exacerbation) as defined by hospitalization in high-security units, clinical impression and CGI scores of "condition much worsened".
  • Patients will be excluded during the study if they will remove their informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00148447

Iulian Iancu
Beer Yaakov, Israel, POB 1
Sponsors and Collaborators
BeerYaakov Mental Health Center
Lundbeck Israel
Principal Investigator: Iulian Iancu, M.D. Beer Yaakov Mental Health Center
Study Chair: Moshe Kotler, M.D. Beer Yaakov Mental Health Center
  More Information

Publications: Identifier: NCT00148447     History of Changes
Other Study ID Numbers: Escitalopram-118CTIL
Study First Received: September 6, 2005
Last Updated: May 2, 2007

Keywords provided by BeerYaakov Mental Health Center:
negative symptoms

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents processed this record on August 18, 2017